<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04570891</url>
  </required_header>
  <id_info>
    <org_study_id>H-2008-003-1145</org_study_id>
    <nct_id>NCT04570891</nct_id>
  </id_info>
  <brief_title>Ultrasound-guided FICB for Proximal Femoral Osteotomy in Pediatric Patients</brief_title>
  <official_title>Ultrasound-guided Fascia Iliaca Compartment Block for Proximal Femoral Osteotomy in Pediatric Patients: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective randomized controlled trial aims to examine the effect of fascia iliaca&#xD;
      compartment block on the postoperative pain and opioid consumption in pediatric patients (3y≤&#xD;
      age &lt;18y) who will undergo orthopedics surgery (proximal femoral osteotomy).&#xD;
&#xD;
      Patients will be allocated to either the FICB(Fascia iliaca compartment block + IV PCA) group&#xD;
      or the control group (no block + IV PCA). Fascia iliaca compartment block will be performed&#xD;
      using 0.25% ropivacaine (1mL/kg, MAX 30mL) under ultrasound-guidance at the end of surgery.&#xD;
&#xD;
      The total opioid consumption at 12, and 24 hours after the surgery, and the pain score at 10&#xD;
      min after PACU admin, 1,6,24 hours after the surgery, the total dose of additional rescue&#xD;
      analgesia (intravenous ketorolac or nalbuphine) at 12 and 24 hours after the surgery will be&#xD;
      recorded.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective randomized controlled trial aims to examine the effect of fascia iliaca&#xD;
      compartment block on postoperative pain and opioid consumption in pediatric patients (3y≤ age&#xD;
      &lt;18y) who will undergo orthopedics surgery (proximal femoral osteotomy).&#xD;
&#xD;
      Patients will be allocated to either the FICB(Fascia iliaca compartment block + IV PCA) group&#xD;
      or the control group (no block + IV PCA). Fascia iliaca compartment block will be performed&#xD;
      using 0.25% ropivacaine (1mL/kg, MAX 30mL) under ultrasound-guidance at the end of surgery.&#xD;
&#xD;
      The total opioid consumption at 12, and 24 hours after the surgery, and the pain score at 10&#xD;
      min after PACU admin, 1,6,24 hours after the surgery, the total dose of additional rescue&#xD;
      analgesia (intravenous ketorolac or nalbuphine) at 12 and 24 hours after the surgery will be&#xD;
      recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>total opioid consumption at 12 hours after the end of surgery</measure>
    <time_frame>at 12 hours after the end of surgery</time_frame>
    <description>total opioid consumption at 12 hours after the end of surgery (IV Nalbuphine 1mg = IV Morphine 1mg = IV Fentanyl 10mcg (0.01mg) per kilogram of body weight.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>total opioid consumption at 24 hours after the end of surgery</measure>
    <time_frame>at 24 hours after the end of surgery</time_frame>
    <description>total opioid consumption at 24 hours after the end of surgery (IV Nalbuphine 1mg = IV Morphine 1mg = IV Fentanyl 10mcg (0.01mg) per kilogram of body weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wong-Baker Faces Pain Rating Scale</measure>
    <time_frame>at 10 minutes after the PACU admin, 1hour, 6hours, and 24hours after the end of surgery.</time_frame>
    <description>by Wong-Baker Faces Pain Rating Scale: There are 6 faces in the Wong-Baker Pain Scale. The first face represents a pain score of 0, and indicates &quot;no hurt&quot;. The second face represents a pain score of 2, and indicates &quot;hurts a little bit.&quot; The third face represents a pain score of 4, and indicates &quot;hurts a little more&quot;. The fourth face represents a pain score of 6, and indicates &quot;hurts even more&quot;. The fifth face represents a pain score of 8, and indicates &quot;hurts a whole lot&quot;; the sixth face represents a pain score of 10, and indicates &quot;hurts worst&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numeric rating scale</measure>
    <time_frame>10 minutes after the PACU admin, 1hour, 6hours, and 24hours after the end of surgery.</time_frame>
    <description>by Numeric rating scale: A numerical rating scale (NRS) requires the patient to rate their pain on a defined scale. For example, 0-10 where 0 is no pain and 10 is the worst pain imaginable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total additional dose of nalbuphine</measure>
    <time_frame>at 12hours, and 24hours after the end of surgery.</time_frame>
    <description>Total additional dose of nalbuphine (mg) per kilogram of body weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total additional dose of ketorolac</measure>
    <time_frame>at 12hours, and 24hours after the end of surgery.</time_frame>
    <description>Total additional dose of ketorolac (mg) per kilogram of body weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of side effects of analgesic medications</measure>
    <time_frame>within 24 hours after the end of surgery</time_frame>
    <description>Nausea, Vomit, Constipation, Pruritus, Dizziness, Dry mouth, Sedation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of side effects of ropivacaine</measure>
    <time_frame>within 1 hour after the end of surgery</time_frame>
    <description>Arrhythmia, Hypotension, ST change, Dizziness, Convulsion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>within 14 days after the end of surgery</time_frame>
    <description>Hospital stay (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological Pupil indexTM (NPi)</measure>
    <time_frame>at 1 hour after the end of surgery</time_frame>
    <description>measured by pupillometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pupil constriction velocity (CV)</measure>
    <time_frame>at 1 hour after the end of surgery</time_frame>
    <description>measured by pupillometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extensor hallucis longus function (motor power of extension of the big toe: I-V) at the second postoperative day (POD-2)</measure>
    <time_frame>At the second postoperative day (POD-2)</time_frame>
    <description>Extensor hallucis longus function (motor power of extension of the big toe: I-V) at the second postoperative day (POD-2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intact toe sensory at the second postoperative day (POD-2)</measure>
    <time_frame>At the second postoperative day (POD-2)</time_frame>
    <description>Intact toe sensory at the second postoperative day (POD-2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normal capillary refill time (&lt; 3 seconds) at the second postoperative day (POD-2)</measure>
    <time_frame>At the second postoperative day (POD-2)</time_frame>
    <description>Normal capillary refill time (&lt; 3 seconds) at the second postoperative day (POD-2)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Orthopedic Disorder</condition>
  <arm_group>
    <arm_group_label>FICB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ultrasound-guided fascia iliaca compartment block (0.25% ropivacaine 1mL/kg, Max 30mL) will be provided at the end of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No regional block is provided at the end of surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound-guided fascia iliaca compartment block</intervention_name>
    <description>Ultrasound-guided fascia iliaca compartment block (0.25% ropivacaine 1mL/kg, Max 30mL) will be provided at the end of surgery.</description>
    <arm_group_label>FICB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>No regional block is provided at the end of surgery.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - 36 children aged between 3 and 18 years who undergo proximal femoral osteotomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Complex surgery (other than proximal femoral osteotomy)&#xD;
&#xD;
          -  Allergy to opioid&#xD;
&#xD;
          -  Allergy to local anesthetics&#xD;
&#xD;
          -  Disease in heart, lung, kidney, and liver&#xD;
&#xD;
          -  Coagulation disorder&#xD;
&#xD;
          -  Disease in the central and peripheral nervous system&#xD;
&#xD;
          -  Unstable vital sign&#xD;
&#xD;
          -  Significant renal impairment (Creatinine&gt; 3.0 mg/dl)&#xD;
&#xD;
          -  Significant hepatic impairment (aspartate transaminase&gt; 120 unit/L, alanine&#xD;
             aminotransferase&gt; 120 unit/L)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Young Eun Jang, MD</last_name>
    <phone>082-02-2072-3665</phone>
    <email>na0ag2@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jin-Tae Kim, MD,PhD</last_name>
    <phone>082-02-2072-3665</phone>
    <email>jintae73@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jin-Tae Kim</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin-Tae Kim, MD. PhD</last_name>
      <phone>82-2-2072-3295</phone>
      <email>kimjintae73@dreamwiz.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 24, 2020</study_first_submitted>
  <study_first_submitted_qc>September 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jin-Tae Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Musculoskeletal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

